Retrospective analysis of aspirin's role in the severity of COVID-19 pneumonia

Table 1 Distribution of clinical parameters based on aspirin intake

Patient characteristics		Aspirin		Total (n = 125)	χ2 value	P value
		Taking (n = 38)	Not taking aspirin (n = 87)
Warfarin	Yes	4	5	9	0.90	0.34
	Percentage (%)	3.2	4.0	7.2
	No	34	82	116
	Percentage (%)	27.2	65.6	92.8
Direct oral anticoagulants (NOAC)	Yes	6	9	15	0.74	0.38
	Percentage (%)	4.8	7.2	12.0
	No	32	78	110
	Percentage (%)	25.6	62.4	88.0
P2Y12 inhibitors	Yes	1	5	6	0.56	0.45
	Percentage (%)	0.8	4.0	4.8
	No	37	82	119
	Percentage (%)	29.6	65.6	95.2
Hypertension	Present	32	50	82	8.38	0.004a
	Percentage (%)	84.2	57.4	65.6
	Absent	6	37	43
	Percentage (%)	15.78	42.5	34.4
Hyperlipidemia	Present	30	49	79	5.82	0.016a
	Percentage (%)	78.9	56.32	63.2
	Absent	8	38	46
	Percentage (%)	21	43.6	36.8
Diabetes Mellitus	Present	18	23	41	5.25	0.022a
	Percentage (%)	47.36	26.4	32.8
	Absent	20	64	84
	Percentage (%)	52.6	73.5	67.2
Immunosuppression	Yes	3	4	7	0.54	0.46
	Percentage (%)	7.8	4.5	5.6
	No	35	83	118
	Percentage (%)	92.1	95.4	94.4
ICU admission	Admitted to ICU	9	38	47	4.50	0.034a
	Percentage (%)	23.6	43.67	37.6
	Remained on medical floors	29	49	78
	Percentage (%)	90.6	56.3	62.4
Intubation	Yes	5	21	26	1.93	0.16
	Percentage (%)	13.1	24.1	20.8
	No	33	66	99
	Percentage (%)	86.8	75.8	79.2
Outcome (survival)	Survived	26	66	92	0.75	0.38
	Percentage (%)	68.4	75.8	73.6
	Died	12	21	33
	Percentage (%)	31.5	24.1	26.4
PE/DVT	Present	2	1	3	1.91	0.16
	Percentage (%)	5.2	1.1	2.4
	Absent	36	86	122
	Percentage (%)	94.7	98.8	97.6
Oxygen use	Present	36	73	109	2.77	0.096
	Percentage (%)	94.7	83.9	87.2
	Absent	2	14	16
	Percentage (%)	5.2	16	12.8

^aP ≤ 0.05.